GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May
May 16 2016 - 7:00AM
GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the
Company”), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, today announced that
Justin Gover, GW’s Chief Executive Officer, will present at the
2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at
8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City.
A live audio webcast of the presentation will be
available through GW’s corporate website in the investor relations
section from the investor’s calendar of events page at
www.gwpharm.com. A replay will be available soon after the live
presentation.
About GW Pharmaceuticals
plc
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW commercialized the
world’s first plant-derived cannabinoid prescription drug,
Sativex®, which is approved for the treatment of spasticity due to
multiple sclerosis in 28 countries outside the United States. GW is
advancing an orphan drug program in the field of childhood epilepsy
with a focus on Epidiolex® (cannabidiol), which is in Phase 3
clinical development for the treatment of Dravet syndrome,
Lennox-Gastaut syndrome and Tuberous Sclerosis Complex. GW has a
deep pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for glioma, type 2
diabetes, schizophrenia and epilepsy. For further information,
please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
(Today) +44 20 3727 1000 |
Stephen
Schultz, VP Investor Relations (U.S.) |
917 280
2424 / 401 500 6570 |
|
|
FTI Consulting (Media Enquiries) |
|
Ben
Atwell / Simon Conway |
+ 44 20
3727 1000 |
FleishmanHillard (U.S.
Media) |
|
Paddi
Hurley / Adam Silverstein |
212 453
2382 / 917 697 9313 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024